Selective vulnerability of motoneuron and perturbed mitochondrial calcium homeostasis in amyotrophic lateral sclerosis: implications for motoneurons specific calcium dysregulation

Manoj Kumar Jaiswal

Abstract

Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disorder characterized by the selective degeneration of defined subgroups of motoneuron in the brainstem, spinal cord and motor cortex with signature hallmarks of mitochondrial Ca\(^{2+}\) overload, free radical damage, excitotoxicity and impaired axonal transport. Although intracellular disruptions of cytosolic and mitochondrial calcium, and in particular low cytosolic calcium ([Ca\(^{2+}\)]) buffering and a strong interaction between metabolic mechanisms and [Ca\(^{2+}\)]; have been identified predominantly in motoneuron impairment, the causes of these disruptions are unknown. The existing evidence suggests that the mutant superoxide dismutase1 (mtSOD1)-mediated toxicity in ALS acts through mitochondria, and that alteration in cytosolic and mitochondria-ER microdomain calcium accumulation are critical to the neurodegenerative process. Furthermore, chronic excitotoxicity mediated by Ca\(^{2+}\)-permeable AMPA and NMDA receptors seems to initiate vicious cycle of intracellular calcium dysregulation which leads to toxic Ca\(^{2+}\) overload and thereby selective neurodegeneration. Recent advancement in the experimental analysis of calcium signals with high spatiotemporal precision has allowed investigations of calcium regulation in-vivo and in-vitro in different cell types, in particular selectively vulnerable/resistant cell types in different animal models of this motoneuron disease. This review provides an overview of latest advances in this field, and focuses on details of what has been learned about disrupted Ca\(^{2+}\) homeostasis and mitochondrial degeneration. It further emphasizes the critical role of mitochondria in preventing apoptosis by acting as a Ca\(^{2+}\) buffers, especially in motoneurons, in pathophysiological conditions such as ALS.

Keywords: Amyotrophic lateral sclerosis (ALS), Motoneuron, Calcium dysregulation, Mitochondria, ER-mitochondria calcium cycle (ERMCC), Selective vulnerability, Calcium buffering, Multifactorial disease, Multidrug therapy

Introduction

Amyotrophic lateral sclerosis (ALS) is an incurable, adult-onset, deadly neurodegenerative disorder distinguished by the progressive degeneration of a defined motoneuron (MN) population in the brain stem, spinal cord and motor cortex. ALS leads to paralysis, atrophy and death within 5 years [1]. Currently, there are no effective drug formulations for cures and riluzole is the only FDA approved treatment available for this devastating disease. The majority of ALS cases are sporadic, but ~10% of ALS cases are familial ALS (fALS). About 20% of these familial cases are caused by dominantly inherited mutations in the gene encoding the enzyme Cu/Zn-superoxide dismutase (SOD1) and are the most common [2]. Mutations in a number of other genes also cause familial ALS; including mutations in autosomal dominant familial MN disease include fALS types 3 [3], 5 [4], 6 or FUS gene [5,6], 7 [7], 8 [8], 9 or ANG gene [9], 10 or TDP-43 (TARDBP gene) [10-12], 11 or Figure four gene [13], NF-H gene [14], DAO gene [15], X-linked [16], C90RF72 [17-19], alsin [20] and MND with FTD [21].

Unfortunately, the discovery of these mutant genes has not yet advanced into useful ALS model organisms,
allowing most work described in literature have been conducted on mutant SOD1 cells, rodents or on patients (both familial and sporadic). Although the process of MN degeneration both in sporadic and familial forms is still little understood, it is generally agreed that there are cell-specific features, particularly impaired uptake of Ca\(^{2+}\) into mitochondria and low content of Ca\(^{2+}\) binding proteins which modulate physiological as well as pathophysiological processes and may render MNs selectively vulnerable to degeneration [22-25]. In both SOD1-mediated and sporadic sALS, reports demonstrate that mitochondrial alterations, including morphological changes, enhanced activity of complexes I, III, and IV, and increased reactive oxygen species (ROS) generation, are key factors in its pathogenesis [8,26-30]. These factors are further exacerbated by observations indicating that the impaired spinal cord and vulnerable spinal cord neurons trigger the functional decline of MNs in neighboring regions, leading to the onset of pathology in ALS [31-34]. The breakdown of mitochondrial membrane potential (\(\Delta \Psi_m\)), excitotoxic stimulation of AMPA/kainite receptors and age associated MN damage reported by several groups may also be a factor to ALS pathogenesis [35-38].

Impaired intracellular Ca\(^{2+}\) homeostasis, rather than direct mitochondrial disruption, is supported by observations that neurons lost early in the disease progression have intrinsically poor cytoplasmic Ca\(^{2+}\) buffering capabilities, due to the absence of Ca\(^{2+}\) binding proteins such as calbindin D\(_{28K}\) (CB-D\(_{28K}\)) and parvalbumin (PV) [22,36]. These findings are in agreement with observations that low cytosolic Ca\(^{2+}\) buffering ability acts as a primary risk factor for MN deterioration, while increases in cytosolic Ca\(^{2+}\) buffering capacity protects vulnerable MNs from degeneration, both in-vitro and in-vivo [25,36,39,40]. In addition to the mechanisms of Ca\(^{2+}\) toxicity present in most cell types, there are several other characteristics of neurons that make them especially vulnerable. Disturbances of glutamate-mediated neurotransmission and the subsequent glutamate release triggered by Ca\(^{2+}\) entry [41] increase extracellular glutamate levels leading to excitotoxicity. This problem is further compounded by reduced glial glutamate uptake caused by oxidative damage to excitatory amino acid transporter 2 (EAAT2) [42]. Studies of fALS in cell lines and in various mouse models that induce Ca\(^{2+}\) disturbance via the inhibition of glial glutamate transport by mtSOD1 yield phenotypes similar to effects proposed in sALS [43]. In addition, in cell culture experiments, partial protection was also obtained by treatment with the Ca\(^{2+}\) channel-blocker nifedipine, implicating Ca\(^{2+}\) entry through voltage-gated Ca\(^{2+}\) channels in mediating the toxicity of mtSOD1\(_{G93A}\) in MNs [44]. In addition to damaging the cell of origin, ROS generated in MNs can cross the plasma membrane and damage glutamate transporters in neighboring astrocytes [41,45]. Further evidence also indicates that the patients with minor SOD1 mutations had the shortest disease durations. In other words, an accelerated disease course is found for the mutants that are more functionally impaired. Since hydrogen peroxide plays an essential role in the formation of SOD1 monomers, dissociation of the dimeric SOD1 molecule monomers should be as essential important process for APS pathogenesis [46].

However, in ALS pathology, the cause of dysfunction has become highly contentious after latest discoveries where ALS astrocytes were shown to secrete substances that are selectively toxic to MNs [47,48]. This means that multiple cell types are involved in the disease process. By adding or deleting mtSOD1 in specific cell types e.g. astrocytes [49,50], microglia [51], schwann cells [52], motor neurons [53] and fibroblast [54] it is possible to influence the disease. Nonetheless, MNs are the cells that directly cause the loss of muscle and limb movement. It is shown that mtSOD1 expressed solely in MNs is sufficient to kick off the disease, although disease progression is slow compared to ubiquitous expression of mtSOD1 [53]. In patients, MNs in the motor cortex, HMsNs and FMsNs of brain stem and spinal cord undergo cell death selectively. There are a number of hypothesis that explain cell type selectivity, including the extraordinary long axons, the large soma and the poor intracellular calcium buffering capacity and excitotoxicity. It is the latter hypothesis that shall be elaborated on in this review, the only mechanism proved to play a role in patients. Calcium, which causes neuronal death in excitotoxicity, can originate from either the extracellular space or from intracellular stores. In general resting calcium in the extracellular space is ~3–4 orders of magnitude higher than in the intracellular stores [55]. As reported previously, MNs are excited by glutamate from the pre-synaptic neuron that binds to glutamate receptors on the postsynaptic MN, which are, among others, the AMPA receptors (AMPA\(_R\)). The AMPA\(_R\) found on MNs are mainly calcium permeable in vitro and in-vivo [56-59], which may explain the selective vulnerability of MNs to excitotoxic cell death. In addition, extracellular calcium entry via these calcium permeable AMPA\(_R\) is responsible for selective MN death, as MN death is inhibited by selective blockers of calcium permeable AMPA\(_R\) [57,58].

Also, electrophysiological experiments showed that the AMPA\(_R\) receptors of MNs had a lower rectification index and a higher relative calcium permeability ratio than other neurons [59]. In conclusion, MNs express calcium permeable AMPA\(_R\) receptors, which could partially explain their pronounced and selective vulnerability to excitotoxic insults [59]. Further explanation for selective MN vulnerability in this cell type has to deal with the increased amount of intracellular calcium. Studies into the calcium homeostasis in MNs have shown a diminished calcium buffering capacity distinguishing ALS-vulnerable from
resistant MN types. To begin with, ALS-vulnerable spinal and brain stem MNs in mice display a low endogenous calcium buffering capacity as demonstrated by patch clamp and microfluorometric calcium measurements [60,61]. In addition, ALS-resistant oculomotor neurons contain a larger calcium buffering capacity than ALS-vulnerable MNs, as measured by similar microfluorometric calcium measurements [62].

The kinetics of calcium signals in MNs are shaped by multiple mechanisms including Ca\textsuperscript{2+} influx, Ca\textsuperscript{2+} uptake and release phenomenon, MN specific Ca\textsuperscript{2+} buffering and extrusion across cellular membrane and microdomains in vicinity [63,64]. Over the past decade, there has been an increased understanding of local communications between Ca\textsuperscript{2+} microdomains and its upstream and downstream target signaling pathways. In particular, an impaired interaction between calcium signaling and mitochondrial processes has been identified as one cellular factor contributing to neurodegenerative processes like those found in motoneuron diseases. In addition, previous studies also indicate the importance of calcium and mitochondria for normal physiological function of MNs [62,65]. Under pathophysiological conditions, low [Ca\textsuperscript{2+}]i buffering and a robust interaction between metabolic processes and [Ca\textsuperscript{2+}]i have been related with selective and severe MN damage resulting from excitotoxic stress and disruptions of cellular and mitochondrial Ca\textsuperscript{2+} homeostasis [66,67]. Considering the prime participation of mitochondria not only in calcium homeostasis directly but also in the energy transduction (to operate other Ca\textsuperscript{2+} clearing mechanisms) and in enacting apoptosis, this aspect of cellular function is of immense importance.

The influence of mitochondrial dysfunction on intracellular Ca\textsuperscript{2+} homeostasis and its role in MN death are fascinating issues that warrant in depth debate. Despite rigorous research, since description of ALS by Charcot ~ 130 years ago, the cellular and molecular abnormalities, which lead to loss of specific MNs, are still dodging the scientific community. Obviously, unraveling the connecting association between mitochondrial dysfunction, calcium dysregulation, and neuronal demise is vital for the understanding of ALS pathogenesis. The aim of this review is to discuss and determine the role of mtSOD1 toxicity in cellular Ca\textsuperscript{2+} homeostasis and mitochondrial dysfunction in MNs of ALS. This review will focus on what has been learned about motoneuron specific calcium dysregulation and perturbed cellular calcium homestasis in ALS from genetically modified animals and cell culture models. Taken together, this review proposes an integrative view, describing mechanisms and critical elements of the pathology of mtSOD1-mediated motoneuron degeneration in ALS.

Review
Disease mechanism in amyotrophic lateral sclerosis
Many pathophysiological mechanisms have been suggested to play a role in the etiology of ALS. Corresponding to clinical features, ALS is characterized by a progressive loss of spinal, brains stem and cortical MNs. MN damage as a result of oxidative stress and excitotoxicity is one of the key hypothesis in ALS etiology. The present evidence also supports the hypothesis of mitochondrial dysfunction acting with oxidative stress to cause neurodegeneration via apoptotic mechanisms. Oxidative stress is also linked with other suggested disease mechanisms such as excitotoxicity causing an increase in [Ca\textsuperscript{2+}]i, which subsequently leads to increased nitric oxide formation. Peroxynitrite, produced by the reaction of superoxide anions and nitric oxide, can consequently lead to oxidative disruption [42]. Glutamate excitotoxicity is another mechanism implicated in ALS pathogenesis through disruption of [Ca\textsuperscript{2+}]i homeostasis and free radical production. For example, in human ALS (hALS), overexpression of glutamatergic synapses leading to excessive Ca\textsuperscript{2+} influx has been linked with MN degeneration [68]. The oxidative stress manifested in ALS might also prop up increased excitotoxicity, as glutamate transporters are predominantly susceptible to disruption by oxidants, and oxidative modifications to the transporters have been reported in ALS and the mtSOD1 mouse model [69]. The roles of individual cellular domains at the organelle level suggest that high calcium buffering enhances MNs vulnerability [70,71]. In summary, ALS comprises the interplay of numerous mechanisms from initiation and spread of MN cell death by mitochondrial dysfunction and/or by enhanced MN excitability by intracellular calcium overload. Therefore the etiology of the disease is most likely to be multifactorial [72,73]. This article will focus on and further discuss the hypothesis and key mechanism that have been most influential in the present and past decade of ALS research.

Oxidative stress sensitivity and mitochondrial dysfunction
Oxidative stress occurs from an imbalance between the production of ROS and the ability of the system to remove ROS or repair the damage caused because of it, and to reinstate the existing reducing ambiance [68]. Oxidative stress and mitochondrial dysfunction are implicated in the pathogenesis of both normal aging and neurodegenerative diseases. There is ongoing debate as to whether oxidative stress is a primary cause of degeneration or it is merely an end result of some other toxic insult. Although oxidative stress is implausible to be the solitary cause of disease initiation, in several cases it may be enhance vulnerability of homeostatic control mechanisms from handling with a toxic insult into a vicious cycle of cellular insults that results in MN degeneration. MN damage as a consequence
of oxidative stress is supposed to be the key premise in ALS. A number of studies have established the existence of elevated oxidative metabolism in ALS, for example finding of increased biochemical markers of oxidative injury in post-mortem samples from ALS patients [38]. Free radical scavenging proteins like SOD1, mitochondrial manganese SOD (SOD2), catalase, and cytochrome c can neutralize free radicals but can not prevent cellular damage by ROS [38,72]. Increased OH generation may occur as an end result of either enhanced peroxidase activity or decreased Cu-binding affinity of mtSOD1. mtSOD1 transgenic (Tg) mice show elevated levels of protein and lipid oxidation at both pre- and post-symptomatic stages of MN dysfunction [74,75]. Oxidative stress is also associated with many other proposed disease mechanisms such as excitotoxicity and axonal transport defects [76-80]. Studies suggest that ROS generated in MNs can cross the plasma membrane to produce oxidative damage to glutamate transporters in neighboring astrocytes via the excitotoxic stimulation of AMPA/kainate receptors, followed by locally restricted excitotoxicity. This initiates a vicious cycle of MN overactivation causing damage, which in turn further activates MNs [37,46,62].

Morphological and ultrastructural abnormalities observed in mitochondria of both, sporadic and familial forms of ALS point towards a crucial involvement of mitochondria in ALS [81-84]. Localization and aggregates of SOD1 in mitochondria of transgenic mouse models were shown previously [85-87]. There are now several observations suggest that mitochondria play a crucial role in disturbing energy metabolism by predisposing calcium-mediated excitotoxicity, leading to ROS generation and initiation of the apoptotic pathway, thereby jeopardizing cell function and normal cellular metabolism [88,89]. Defects in mitochondrial function have been found in ALS and some sALS by histopathological observations of mitochondrial swelling and vacuolization in ALS transgenic mouse models and in ALS patients [28,30,31,39,62,90]; Figure 1A. Morphological abnormalities were not only confined to CNS, but were also found in skeletal muscles, intramuscular nerve fibers and proximal horns of the spinal cord [91-93]. Recently, in a SOD1-transfected cell culture model of MN disease, our laboratory has shown impairment of mitochondrial calcium handling and impaired cross-talk between mitochondria-endoplasmic reticulum (ER) microdomains [94]; Figure 1B-D. Many other studies have recently focused on mitochondrial dysfunction, specifically on the increased activity of the mitochondrial respiratory chain necessary for ATP synthesis, resulting in an increased ROS production. Furthermore, the excessive electron transport chain activity can deplete energy stores, resulting in the loss of integrity of neuronal cell membranes and leaving them permeable to ions and water which can cause damage. Deficits in the activities of complex I and complex IV, as a result of mutations in mitochondrial DNA, have been identified in the skeletal muscles and spinal cord of sALS patients [33,95,96].

The query of whether changes in the mitochondrial genome can cause variations in mitochondrial function has been addressed by transferring mitochondrial DNA from ALS subjects to mitochondrial DNA-depleted human neuroblastoma cells. This manipulation resulted in anomalous electron transport chain function, increases in the activity of free radical scavenging enzymes, disturbed Ca\(^{2+}\) homeostasis and altered mitochondrial structure, suggesting a pathophysiological role for mitochondrial DNA mutations in different forms of ALS [94,97]. A striking recent set of publications provides evidence that mtSOD1 might disrupt the association of respiratory complex IV (cytochrome c) with the inner mitochondrial membrane, thus obstructing the mitochondrial respiratory system. Cultured MNs expressing mtSOD1 and MNs in ex-vivo brain slices where respiratory chain complex IV was blocked by cyanide or azide also shows mitochondrial involvement [98-100].

The major question of whether mitochondrial anomalies are involved in the disease progression or simply a derivative of neuronal degeneration is still far from over. Pathological features like the occurrence of membrane-bound vacuoles in MNs in Tg mice expressing G93A or G37R suggest that mitochondrial alterations are an early consequence eliciting the beginning of the disease, instead of merely a derivative of neuronal degeneration [101,102]. Mitochondrial vacuolization occurs by detachment of the outer membrane from the inner membrane and increase of the intermembrane space, confirmed by biomarkers studies for mitochondrial compartments. After membrane expansion, mature vacuoles form which leads to the inner membrane disintegrations [103,104]. A recent publication demonstrates the localization of a significant fraction of SOD1 in intermitochondrial space thereby causing toxicity. Inhibition of mitochondrial respiratory metabolism is reported in Tg ALS mice models [105,106]. Certainly, MNs are highly susceptible to mitochondrial damage. Studies using mitochondrial respiratory chain inhibition by cyanide and azide result in selective MN death, which can be counteracted by ROS scavengers and AMPA\(_R\) blockers [62,107]. Furthermore, ALS-like symptoms can be induced by deletion of vascular endothelial-cell growth factor (VEGF) that eliminates the ability to respond to tissue mild and chronic hypoxia [108-110]. Cross-breeding these mice with the mtSOD1 severely enhanced MN degeneration, while treatment of SOD1-Tg mice with VEGF hindered progression of disease symptoms and extend mice survival [62,111-117].
Characteristically low Ca\(^{2+}\) buffering capacity of motoneurons and its impact on selective motoneuron vulnerability in amyotrophic lateral sclerosis

Several groups have reported that the disruption of intracellular Ca\(^{2+}\) homeostasis plays a prominent role in the etiology of ALS. The involvement of Ca\(^{2+}\) as a risk factor was suggested by the observation that Ca\(^{2+}\)-binding proteins such as CB-D\(^{28k}\) and PV were absent in MN populations lost early in ALS. In contrast, MNs less prone to damage expressed markedly higher levels of calcium-binding proteins CB-D\(^{28k}\) and/or PV [22,62], and were relatively insensitive to mitochondrial calcium buffering. In dorsal vagal neurons, which contain an abundance of Ca\(^{2+}\) sequestering proteins [118], the delay in the decay time constant (\(\tau\)) of Ca\(^{2+}\) transients (FCCP influx) is not caused by mitochondrial permeability. This observation identified a low cytosolic Ca\(^{2+}\) buffering capacity as an important risk factor for MN degeneration. Data from different groups shows that the vulnerable populations of MNs display low endogenous calcium buffering capacity [119], due to low expression levels of Ca\(^{2+}\)-buffering proteins. Although potentially essential under physiological conditions, as it allows for rapid Ca\(^{2+}\) transients relaxation times during high frequency rhythmic activity, these characteristics make MNs more susceptible to an excessive influx of Ca\(^{2+}\) ions. This susceptibility increases

---

**Figure 1** Mitochondrial structure of motor neurons in mutant SOD1 transgenic mice and calcium load in microdomains in a cell culture model of motoneuron disease. (A) Shows abnormalities like dilated cristae (asterisk) and leaking outer membrane (adapted from ref. 31). (B-D) The simultaneous measurement of cytosolic calcium (Fura-2) and mitochondrial calcium (Rhod-2) concentrations in WT and G93A transected SH-SYSY cells during FCCP-evoked mitochondrial Ca\(^{2+}\) release. (B) The kinetic profile of the FCCP-evoked Ca\(^{2+}\) release in the WT transfected SH-SYSY neuroblastoma cells; the cytosolic (Error bar green, black square trace) and mitochondrial (Error bar red, black circle trace) compartment were measured simultaneously. The trace represents the mean of 5 cells in focus stimulated with 2 \(\mu\)M FCCP. (C) The corresponding kinetic profile of the FCCP-evoked Ca\(^{2+}\) release in the G93A transfected SH-SYSY neuroblastoma cells; the cytosolic (Error bar green, black square trace) and mitochondrial (Error bar red, black circle trace) compartment were measured simultaneously. The trace represents the mean of 5 cells in focus stimulated with 2 \(\mu\)M FCCP. FCCP-evoked [Ca\(^{2+}\)]mito signals were smaller in amplitude and exhibited slower kinetics in G93A transfected SH-SYSY cells compared to WT transfected cells and were altered from [Ca\(^{2+}\)] efflux. (D) A bar diagram of the cytosolic (green bar) and mitochondrial (red bar) fluorescence signals (F/F0) from WT (F/F0 = 0.1569 ± 0.023S for [Ca\(^{2+}\)]i and F/F0 = 0.01069 ± 0.01811 for [Ca\(^{2+}\)] mito; hollow; N = 5, n = 17) and G93A (F/F0 = 0.01098 ± 0.02469 for [Ca\(^{2+}\)]i and F/F0 = −0.00486 ± 0.00043 for [Ca\(^{2+}\)] mito; striped pattern; N = 6, n = 17) transfected SH-SYSY neuroblastoma cells. Values represent means ± SD, **p < 0.001. N = Number of experiments; n = Number of cells (adapted from ref. 94).
the risk of activation of excitotoxic second messenger cascades and related cellular damages [62,119]. Another argument in favor of this hypothesis is that high concentrations of mobile buffers accelerate the distribution of local Ca$^{2+}$ gradients by a mechanism known as buffering diffusion (Figure 2A, B). According to this concept, under pathophysiological conditions, differential buffering reflects a basic diversity in the spatio-temporal organization of Ca$^{2+}$ signaling rather than a singular difference in single cellular parameter [120-122]. Likewise, an increase in [Ca$^{2+}$]$\text{i}$ buffering capacity could defend vulnerable MNs and protect from degeneration both in vitro and in-vivo [25,123].

**Figure 2** Ca$^{2+}$ homeostasis and its correlation with weakly and strongly buffered motoneurons under physiological and pathophysiological conditions. (A) The Ca$^{2+}$ buffering capacity ($K_B$) of a cell, reflecting relative fraction of bound versus free Ca$^{2+}$, can be calculated by using the ‘added buffer’ approach by linear one-compartment model. The recovery time of [Ca$^{2+}$]$\text{i}$, elevations ($\tau$) depends on the amount of endogenous buffer ($S$; denotes Ca$^{2+}$-binding proteins), the amount of exogenous buffer (B; i.e. Fura-2) and the transport rate ($\gamma$) of Ca$^{2+}$ across cellular membranes. $K_B$ indicates the buffer capacity of the exogenous buffer (i.e. Fura-2). (B) Ca$^{2+}$ homeostasis in weakly and strongly buffered MNs. The amplitude of Ca$^{2+}$ transients is several times larger in weakly buffered cells (e.g. HMNS and SMNs) than in strongly buffered cells (e.g. oculomotor neurons), and the recovery time is significantly accelerated ($\tau$). (C) Low Ca$^{2+}$ buffering in ALS-vulnerable HMNs exposes mitochondria to higher Ca$^{2+}$ loads; increase the risk for mitochondrial damage. This triggers mitochondrial production of reactive oxygen species (ROS), which then inhibit glial EAAT2 function. This leads to further increase in glutamate concentrations in the synapse and further rises in post-synaptic calcium levels which contributes to the selective vulnerability of MNs in ALS. Low cytosolic Ca$^{2+}$ buffering capacity promotes Ca$^{2+}$ accumulation and formation of subcellular domains around influx sites (red), and thus facilitates the interaction of elevated calcium levels with intracellular organelles such as mitochondria (modified from refs. [62-63,73,94,118]).
In order to check whether cytosolic [Ca\textsuperscript{2+}]i buffering can protect cells from dysfunction and degeneration, our group performed Ca\textsuperscript{2+} imaging studies following a depolarization stimulus (60 mM K\textsuperscript{+}) in primary neuronal cells obtained from mice cortex at E18 expressing low and high CB-D28k. Results show that indeed CB-D28k buffer [Ca\textsuperscript{2+}]i where low CB-D28k transfected neuronal cells display a significant (\sim 2 times) reduction in the peak amplitude of the sustained [Ca\textsuperscript{2+}]i increase compare to high CB-D28k transfected neuronal cells (data not shown). τ in CB-D28k transfected cells is also slower (\sim 60s) compared to non-transfected cells where baseline recovery time is \sim 30-35 s while showing little differences in the area under the time - concentration curve (AUC). This observation is in good agreement with the low buffering hypothesis which states that low buffer capacity allows for rapid Ca\textsuperscript{2+} dynamics during physiological activity, but represents a significant risk factor during ALS-related MN disease [124]. The observation of high cytosolic buffering capacity in selectively resistant MNs is consistent with earlier immunocytochemical studies of endogenous calcium buffering proteins. Moreover, in-vitro cell culture models have shown that elevated [Ca\textsuperscript{2+}]i buffer concentration reduces ALS specific MN damage providing further support in favor of the notion that increased buffer concentrations create beneficial protection [125]. The low Ca\textsuperscript{2+} buffering properties synergize with a high AMPA/kainate current density to clarify the susceptibility of MNs to increased stimulation by glutamate and associated Ca\textsuperscript{2+} influx [59,126]. Earlier observation also indicates interactions of mitochondrial proteins e.g. VAPBP56S and PTPIP51 implicated in regulating calcium homestasis [127,128].

In the absence of adequate cytoplasmic buffering, or in cases where the existing cytoplasmic buffering system is overwhelmed, there is a shift in mitochondrial Ca\textsuperscript{2+} uptake from a beneficial physiological regulatory mechanism to a possibly detrimental process leading towards MNs death. In this process MNs death is clearly Ca\textsuperscript{2+} dependent. The downstream mechanism that links the rise in [Ca\textsuperscript{2+}]i to MNs death is not clear though these processes have been mostly credited to mitochondrial Ca\textsuperscript{2+} accumulation or glutamate excitotoxicity. Whether the change in ΔΨ\textsubscript{m} is simply an inevitable consequence of an unusually enormous Ca\textsuperscript{2+} load or there is other downstream pathway contributing to glutamate response is not known yet, however depolarisation of ΔΨ\textsubscript{m} is one consequences of it. Data also suggested the role for other factor in addition to Ca\textsuperscript{2+} such as nitric oxide synthase (NOS) inhibitors. Results also suggest that mitochondrial damage arbitrated at least in part by Ca\textsuperscript{2+} induced MPTP opening and may contribute to surge of neighbouring cell activation. In conclusion, we believe that two of the most important features for MNs in ALS are: (i) low buffer capacity generates exceptionally large Ca\textsuperscript{2+} domains, but not in case of serious end stage ALS like symptoms and (ii) in ALS vulnerable MNs buffering capacity critically depends upon the domain size of mitochondria and ER. Therefore, we proposed a model where a portion of MN mitochondria interacts with areas of high [Ca\textsuperscript{2+}] around influx sites due to low buffering induced excitotoxicity shown in Figure 2C.

Another proposed factor for calcium disregulation could be an ALS-related immune response targeted at voltage-dependent calcium channels (VDCC), where a disruption of Ca\textsuperscript{2+} homeostasis results from compromised voltage-dependent calcium influx [129]. Furthermore, synaptic glutamate transport is also believed to be involved in other forms of ALS and related MN neurodegeneration. In cell-culture, limited protection was achieved by treatment with nifedipine, implicating Ca\textsuperscript{2+} entry through voltage-gated Ca\textsuperscript{2+} channels, in addition to glutamate receptors, in mediating the toxicity of mtSOD1 in MNs. The crucial role of Ca\textsuperscript{2+}-permeable AMPA\textsubscript{K} was further emphasized by cross-breeding of Tg SOD1 mice with mice that exhibited markedly reduced Ca\textsuperscript{2+} permeability of AMPA/kainate receptors, due to GluR2 overexpression [45,126]. Finally, impaired mitochondrial calcium transport capacity in mtSOD1 mice may play an important role. Firstly, it links mitochondrial dysfunction to glutamate excitotoxicity and secondly, elevation of [Ca\textsuperscript{2+}]\textsubscript{c} concentrations in neurons compromises mitochondrial integrity and function by inducing enhanced production of ROS from mitochondria [130]; Figure 2C.

**Glutamate transmission and excitotoxicity**

Glutamate is known as the predominant excitatory neurotransmitter in the CNS acting at both ionotropic and metabotropic receptors. It is synthesized and stored in synaptic nerve components and released in response to depolarization of the neuron. Excessive glutamate exposure is toxic to neurons via glutamate-triggered Ca\textsuperscript{2+} influx [73,131]. Several lines of proof implicate increases in glutamate neurotransmission and glutamate-triggered Ca\textsuperscript{2+} entry as significant ALS risk-factors. Increased extracellular glutamate levels result from reduced glial glutamate uptake due to oxidative damage to excitatory amino acid transporter 2 (EAAT2) or by aberrations in its production. Increased glutamate levels in the cerebrospinal fluid (CSF) of a subset of ALS patients have been shown by many groups. The elevation of this glutamate level may be attributed to deficient glutamate transporter capacity (loss of EAAT2 function), as low levels of the transport protein have been found in some post mortem ALS brains [66,73,132]. Furthermore, glutamate uptake inhibitors causes selective MN damage in organotypic slices [66] and in dissociated spinal cord culture [133], suggesting...
that reduction of glutamate transport could contribute to the MN damage seen in the ALS disease. The leading argument for a role of glutamate excitotoxicity in ALS is the efficacy of FDA approved drug riluzole, the lone drug which proved effective against disease progression in patients and has anti-excitotoxic properties. It was shown that riluzole inhibits the release of glutamate through the inactivation of voltage-dependent Na+ channels on glutamatergic nerve terminals as well as to activate a G-protein-dependent signal transduction cascades.

In-vivo evidence for a possible role of GluR1-4 (AMPA receptor subunits) in ALS comes from several studies. Transgenic mice lacking GluR2 (GluR2 subunit is a component in the AMPA receptor complex, which renders them particularly impermeable to calcium) do not hurt from MN disease. This suggests that a low GluR2 level is a modifier of MN degeneration rather than being sufficient to cause ALS [134]. Furthermore, glutamate excitotoxicity in sALS is caused by a selective loss of astrocytic glutamate transporter-1 (GLT-1) and is reproduced in mice by knockout of GLT-1, a homologue of EAAT-2 [135]. Oral administration of glutamate inhibitors prolonged the life span of SOD1G93A mice [136]. Further studies have pointed to the significance of GluR2 in neuronal survival, in which alterations in RNA editing at the Q/R site lead to the generation of a lethal phenotype involving seizure and acute neurodegeneration [137]. Furthermore, Glu2-N overexpression induces a progressive decline in the function of spinal cord, most likely due to the long-onset degeneration of spinal MNs [138].

Mechanism underlying mitochondria-ER Ca2+ stores coupling

Diverse microdomain intracellular pools contribute in causing Ca2+ signals in neuronal cells and in shaping their spatio-temporal patterns and cell fate. Kinetic and “hot spot” hypothesis of mitochondria, different channels with distinct properties and highly defined expression patterns on ER are all capable of regulating [Ca2+]i in many systems [139,140]. In an attempt to understand more about the Ca2+ metabolism of hypoglossal MNs, Jaiswal and colleagues studied the role of the ER in Ca2+ handling where it was shown that the ER in MNs retained a comparatively lower quantity of calcium than mitochondria after [Ca2+]i elevation, indicating a relative inability to sequester Ca2+ in the MNs of SOD1G93A mice as compared to WT counterparts. These results indicate that the conventional Ca2+ storing function of mitochondria is dominating over ER Ca2+ accumulation in these MNs. These results are in good agreement with the “hotspot” hypothesis that suggests that mitochondria preferentially accumulate Ca2+ at microdomains of elevated Ca2+ concentration ([Ca2+]i), predominantly near ER Ca2+ release sites and other Ca2+ channels. Accordingly, mitochondria can affect both Ca2+ release from the ER and capacitative Ca2+ entry across the plasma membrane, thereby shaping the size and duration of the intracellular Ca2+ signal in MNs of WT and SOD1G93A mice. These events determined by the Ca2+ sensitivity of the Ca2+ channels and capability of mitochondria to remove Ca2+ from the subcellular microdomain at the opening of the ion channel. This effect has been confirmed in-vitro, but the condition appears markedly different in various cell models [141,142]. This indicates that several modulatory mechanisms occur, many of which still await reasonable clarification at cellular and molecular level. As discussed above, vast evidence supports the notion that the measured high degree of Ca2+ accumulation of MNs mitochondria in-situ mainly influenced by the vicinity of mitochondria to the ion channels through which Ca2+ enters the cytosol. A fundamental, but still unanswered, question is the precise mechanism by which stochastic versus specific localization of Ca2+ influx occur and the amount to which mitochondrial function differs within different cell types, are critical quest in the field of ALS research.

Mitochondrial dysfunction, Ca2+ homeostasis and ALS: a multifactorial disease mechanism

The Ca2+-dependent signaling mechanisms that result in the enhanced vulnerability of MNs in ALS disease and associated mouse models are also critical for normal cellular function. Earlier studies suggest that unrestrained Ca2+ entry compounded with an inability to sequester this calcium leads to the degeneration of mitochondria in the MNs of the mouse model of ALS [29,31]. In other MNs types have a low Ca2+-buffering capacity because of small concentrations of Ca2+-buffering proteins and a high quantity of Ca2+-permeable AMPAR [126,143-146]. These two properties appear to be specific to MNs and are possibly vital for their normal function. However, this increased sensitivity to calcium also means that MNs are more easily over stimulated by glutamate and astounded by Ca2+. It is unknown whether Ca2+ dependent pathways are different in MNs. More recently, focus was shifted to the role of mitochondria as an effective regulator of [Ca2+]i signals [147,148]. The use of mitochondria-targeted Ca2+ probes reveals a fast, intense surge in free intra-mitochondrial Ca2+ upon cellular stimulation. Increased Ca2+ uptake by mitochondria leads to up-regulation of the enzymes activity in oxidative metabolism, resulting in cell-specific metabolic changes [149-151]. This hypothesis is further strengthened by the appearance of abnormalities in mitochondrial ultrastructure and vacuoles formation resulted from degenerating mitochondria found in post mortem samples of ALS [28-31]. Even though the precise molecular mechanism is still not known,
we hypothesize that MN vulnerability in ALS is a outcome of physiological features, mainly highly specialized $\text{Ca}^{2+}$ surroundings that are required for appropriate neuronal function, uninterrupted activity-dependent mitochondria-ER $\text{Ca}^{2+}$ cycling and the leading role of mitochondria in buffering $\text{Ca}^{2+}$ transients.

In vulnerable MNs, low intrinsic cytosolic $\text{Ca}^{2+}$ buffering requires that mitochondria play the dominant role in the regulation of [Ca$^{2+}$], transients; even during small cytosolic $\text{Ca}^{2+}$ increases, mitochondria are known to take up more than 50% of intracellular $\text{Ca}^{2+}$. Outsized and enduring $\text{Ca}^{2+}$ microdomains around $\text{Ca}^{2+}$ influx sites increase the danger of toxic $\text{Ca}^{2+}$ buildups and a successive activation of $\text{Ca}^{2+}$ dependent neurodegenerative pathways under excitotoxic conditions. Excitotoxicity associated with these influx domains is primarily suppressed by mitochondrial contributions, rather than ER $\text{Ca}^{2+}$ uptake [36,94,99]. The prominent role of mitochondria in regulating adequate $\text{Ca}^{2+}$ loads in MNs has significant implications for pathological conditions such as in ALS. First, the quantity of $\text{Ca}^{2+}$ taken up by the mitochondria is greater in MNs than in many others cell types and therefore MN mitochondria are more susceptible to $\text{Ca}^{2+}$ mediated damage, such as ROS generation [37,46,152]. Second, our experiments provide indication that the restriction of cytosolic $\text{Ca}^{2+}$ to non-pathological levels is determined by intact $\text{Ca}^{2+}$ uptake into mitochondria. Hence, when mitochondrial $\text{Ca}^{2+}$ uptake is disturbed as seen by low $\text{Ca}^{2+}$ uptake in SOD1$^{G93A}$ MNs compare to WT, MNs are directly endangered by elevated $\text{Ca}^{2+}$ levels, especially during high-frequency, repetitive $\text{Ca}^{2+}$ oscillations. The reduced capability to limit $\text{Ca}^{2+}$ transient amplitudes in the cytosol, particularly in local microdomains of extraordinary $\text{Ca}^{2+}$ influx when mitochondria are depolarised, heightens the hazard of initiating $\text{Ca}^{2+}$ dependent neurodegenerative pathways leading to cell demise.

Combining the lessons learned from multiple animal and cell culture models of ALS, the central insight is that mitochondrial dysfunction and $\text{Ca}^{2+}$ homeostasis [152,153] are strong contributors to the selective vulnerability of MNs. Considering the association and significance of mitochondrial dysfunction and $\text{Ca}^{2+}$ homeostasis, we postulate that MN possess large number of voltage and ligand gated $\text{Ca}^{2+}$ channels that, when activated, cause rapid $\text{Ca}^{2+}$ influx. Since cytoplasmic $\text{Ca}^{2+}$ buffering is relatively weak in these cell types, significant demand is placed on MN mitochondria. If the mitochondria are already damaged or weakened, this results in mitochondrial $\text{Ca}^{2+}$ overload and ROS production and in some cases prone for infection [154]. Furthermore, long-lasting $\Delta W_{m}$ depolarisation due to $\text{Ca}^{2+}$ entry can be a basis for the release of pro-apoptotic proteins and activate enzymes involved in apoptotic pathways [155,156].

Multidrug therapies in ALS: where should we focus for the treatment?

Even though scientific discoveries are speeding up with an exceptional pace and years of experimentation using cell cultures, mice and rat made Tg for human mtSOD1 has yielded precious data about the mechanisms that underlie ALS as well as suggestions for therapy, to date approximately ~50 clinical trials have failed and ended with disappointment and frustration. The main cause for the failure to translate experimentation in animals to therapies for patients is that there are too many compounds that increase life span in mice and rats, but fail to improve human patients condition. To increase the chances of success for future clinical trials we might consider the fact that ALS is not simply a multifactorial disease but also a multisystemic disease that is the consequence of a complex neurotoxic mechanism that involves molecular and cellular cross-talk between MNs, glia and astrocytes. Preclinical trials have not yet resulted in favorable outcomes, due to the fact that data are generally collected in animals of the identical age and with the same mutation expressed in a homogeneous genetic background whereas the age of beginning of disease, the progression and the severity of ALS in human patients are heterogeneous, signifying that possible genetic risk factors and modifying causes exist for sALS and certain drugs are effective only if given before onset of the disease [157-159]. In addition, the trial suffers from the deficiency of presumed negative clinical data set, which is different from the null result (i.e. data that do not affect the outcome). Interestingly, in most of the clinical trials, a subset of the patient population showed better condition with the possibility that each clinical trial has been successful within only a select subset of the patient population [158].

It is also important to keep in mind that ALS is a multifactorial disease, and it might be unrealistic to envision that one drug will have a broad spectrum of efficacy on pathologies that are widespread and, at times unrelated. In view of recent findings of a non-cell-autonomous demise of MNs [47,48], design of multi drug combination therapies should be targeted at the intersection of various aspects of this cascade, rather than a single-drug cure [157,158]. We suggest that the forthcoming clinical trials should include combinatorial studies, and that patients who display progress in their condition should not be considered as ‘outliers,’ because they might indeed represent the target population, especially for the drugs tested [157]. Until now animal studies have shown that multi-drug combination therapies and the method of delivery of a drug is also often have synergistic effects in ALS, for example, riluzole administered with melatonin and vitamin E (inhibits Na$^{+}$-current activation and the apoptotic cascade), minocycline administered with creatine (inhibits microglia activation and the apoptotic signaling cascade),...
or treatment with IGF-1 or VEGF retrogradely transported in MNs through viral vectors [111-119,136,158-163]. A substitute to pharmacological cures, the latest developments in stem-cell therapy might offer possibilities for neural grafting in patients with ALS [114,158,164].

The identification and characterization of early detection markers in ALS, and the establishment of dependable biomarkers for disease progression in a select set of clinical trials studies on blood, plasma and cerebrospinal fluid (CSF), obtained from patients and control subjects bounds to improved improved clinical trials [165]. The lessons learned from a decade of research using the mtSOD1 animal model might help scientists in finding cures for neurodegeneration where single-drug treatments have confirmed insufficient for effective treatment of ALS.

Conclusions

In spite of rigorous research for years there are several important questions still unanswered; these include: (a) does the expression of mtSOD1 at physiological levels causes morphological and structural abnormalities of mitochondrial assembly and its calcium buffering capacity? (b) At pathophysiological levels, does the mitochondria-ER and ERMCC Ca2+ sequestration source specificity and spatiotemporal properties of [Ca2+]i signaling varies at sub cellular level in and around microdomain? (c) In the presence of mtSOD1 gene, what are the consequences of alterations in mitochondrial function on Ca2+ homeostasis and ERMCC? Numerous developments and improvements in visualization of diseased MNs and spatiotemporal resolution of mitochondria-ER calcium signaling cascades have the potential to bring novel insights. MN possess numerous Ca2+ channels that cause rapid Ca2+ influx because of comparatively weak [Ca2+]i buffering, results in mitochondrial Ca2+ overload and strong ROS generation in mtSOD1 Mice. Further studies of ER-mitochondria calcium cycle (ERMCC) with targeted calcium probes show a rapid and dramatic increase in free intra mitochondrial and ER calcium. The defects in mitochondrial assembly and vacuoles derived from defective mitochondria found in post mortem ALS patients further support the suggestion. Design of novel antioxidant strategies to selectively target the oxidative stress and redox imbalance is the other avenue need to be explored. Furthermore, check on selective loss of MNs causing the discharge of pro-apoptotic proteins which activate enzymes leads to activation of apoptotic pathways and apoptotic cells observed in MNs of ALS is beneficial. Dysregulation between mitochondria-ER and ERMCC are well known features and therapeutic drugs aiming to stabilize these cycles reduce ROS and oxidative stress and may be effective in wide range of MN diseases. Another nice direction would be to develop so called “smart drugs” and “combination therapies or multi drug therapies” which have multifactorial impact on disease mechanism due to multifactorial nature of ALS disease. Furthermore, it is hypothesized that disrupted Ca2+ homeostasis and oxidative stress induced ROS have a vital role in propagating injury by increasing the excitability of MNs and by targeting neighboring glia. Perhaps as a consequence, excitotoxicity builds up with increased activity-dependent Ca2+ influx and associated mitochondrial Ca2+ cycling. Given the mitochondrial disturbances, Ca2+ buffering becomes inefficient and increase in cytosolic Ca2+ levels. Protective options are to elevate the resistance of MNs to high intracellular Ca2+ concentrations by inducing defense mechanism and/or to inhibit the downstream apoptotic and death cycle pathways activated by increased intracellular Ca2+ concentrations. However, severely impaired MNs are not amenable to taking functional advantage of neuronal protection in ALS.

Therefore perhaps we should focus on new tools such as recently discovered genes that cause ALS and induced pluripotent stem cells taken from ALS patients and derived into MNs to identify potential cytosolic pathways and barriers that could lead to MN degeneration in ALS. Forthcoming studies will hopefully add to the understanding of why these processes preferentially damage MNs and the role non-cell autonomous cell death might play. In conclusion, data indicates that ALS is a multifactorial disease and therefore a combined therapeutic interference (combination therapy) with many facets of target site both at the MNs and glial cells will be most likely essential for survival of ALS patients. While keeping in mind the previous failures in clinical trials for ALS, further studies in this direction to better understand the pathogenesis of cell death in ALS and targeted therapy therefore will be of great interest.

Abbreviations

ALS: Amyotrophic lateral sclerosis; aCSF: Artificial cerebrospinal fluid; AMPA: Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; [Ca2+]i: Cytosolic calcium; CB-D28K: Calbidin D28K; CSF: Cerebrospinal fluid; EAAT2: Excitatory amino acid transporter 2; ER: Endoplasmic reticulum; ERMCC: ER-mitochondria calcium cycle; fALS: Familial amyotrophic lateral sclerosis; FCCP: Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone; FMNs: Facial motoneurons; GluR: Glutamate receptors; GLT: Glutamate transporter; hALS: Human amyotrophic lateral sclerosis; HMsNs: Hypoglossal motoneurons; PV: Parvalbumin; ROS: Reactive oxygen species; SOD1: Cu/Zn superoxide dismutase 1; mtSOD1: Mutant superoxide dismutase 1; MNs: Motoneurons; NMDA: N-Methyl-D-aspartic acid; P: Parvalbumin; Tg: Transgenic; VDCC: Voltage-dependent calcium channels; VEGF: Vascular endothelial-cell growth factor; WT: Wild-type; ΔΨm: Mitochondrial membrane potential; t: Decay time constant.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interests.

Acknowledgments

I would like to thank Drs Bernhard U. Keller, Zygmunt Galdzicki and Fritz Lischka for their valuable discussions. Thanks to Derek Hallman for his insightful comments.
References

1. Rowland LP, Shneider NA: Amyotrophic lateral sclerosis. N Engl J Med 2001, 344:1688–1700.

2. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donahodt D, Go J, O’Regan J, Peng DX, O’Regan J, Deng HX, Rahmani Z, Karzus A, McKenna-Yasek D, Cayabab A, Gaston SM, Berger R, Tazdi IE, Halperin JJ, Heredfeldt B, Van den Bergh R, Hung WY, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Peric-Vance MA, et al: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362(6415):59–62.

3. Hand CK, Khorsi J, Salachas F, Gros-Louis F, Lopes AAS, Mayeux Portas V, Brown RH Jr, Weininger V, Camu W, Roulleau GA: A novel locus for familial amyotrophic lateral sclerosis, on chromosome 19q. Am J Hum Genet 2002, 70(2):251–256.

4. Chance PF, Rabin BA, Ryan SG, Ding Y, Scavina M, Crain B, Griffin JWW, Combath DR: Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 1998, 62(3):633–646.

5. Kowalski TJ Jr, Leclerc AL, Tamaszjan E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarksi EJ, Munstar T, Valdimars P, Roulleau GA, Hosker BA, Correllite D, de Jong PJ, Yoshinaga Y, Haines JL, Peric-Vance MA, Yan J, Tizzic N, Siddique T, McKenna-Yasek D, Sapp PC, Horvitz HR, Landers JE, Brown RH Jr: Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323(5918):1205–1208.

6. Yan J, Deng HX, Siddique N, Fecto F, Chen W, Yang Y, et al: Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology 2010, 75(4):807–814.

7. Sapp PC, Hosker BA, McKenna-Yasek D, Chin W, Gann A, Genie H, Gorenstein J, Huang M, Sailer W, Schaffer M, Valesky M, Haines JL, Peric-Vance MA, Siddique T, Horvitz HR, Brown RH Jr: Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am J Hum Genet 2003, 73(2):397–403.

8. Nishimura AL, Mitme-Neto M, Silva HC, Oliveira JR, Vainzof M, Zatz M: A novel locus for late onset amyotrophic lateral sclerosis/motor neuron disease variant at 20q13. J Med Genet 2004, 41(4):315–320.

9. Greenway MJ, Andersen PM, Russ C, Enni S, Cashman S, Donaghy C, Patterson V, Swijinger R, Kieran D, Prehn J, Morrison KG, Green A, Acharya KR, Brown RH Jr, Hardman CL: ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. Nature Genet 2006, 38(4):411–413.

10. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belloreca J, Mitchell JE, Lingford PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE: TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319(5867):1668–1672.

11. Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ, Kunz C, Crook RJ, Sreedharan J, Vance C, Sorenson E, Lippa C, Bigio EH, Geschwind DH, Knopman DS, Matsuomoto H, Petersen RC, Cashman NR, Hutton MW, Chey WA, Bolin KB, Boeve BF, Grill-Rektor NF, Wszolek ZK, Caselli RJ, Dickson DW, Mackenzie R, Petrucelli L, et al: Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet 2008, 4(9):1000193.

12. Conforti FL, Sproverio W, Simone IML, Mazzei R, Valentino P, Ugozaro C, Magagnato A, Patitucci A, La Bella V, Sproverio T, Tedeschi G, Citrigno L, Aurelio M, Gajewski CD, Martushova K, Kiaei M, Beal MF: The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1998, 36(1):846–858.

13. Jaiswal MK, Keller BU: Cu/Zn superoxide dismutase mutatyp for familial amyotrophic lateral sclerosis increases the vulnerability of mitochondria and perturbs Ca2+ homeostasis in SOD1G93A mice. Mol Pharmacol 2009, 75(4):478–489.

14. Lips MB, Keller BU: Endogenous calcium buffering in motoneuron of the nucleus hypoglossus from mouse. J Physiol 1998, 510(1):105–117.

15. Van Den Bosch L, Schwaller B, Vleminkx V, Meijers B, Stork S, Ruehlke T, Van Houtte E, Kaassen H, Cello MR, Missiaen L: Protective effect of paravilum on excitotoxic motor neuron death. Exp Neurol 2002, 174(2):159–161.

16. Mattson MP, LaFerla FM, Chan SL, Leissring MA, Steple BN, Geiser JD: Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2000, 23(2):222–229.

17. Rindi R, Ribbo H, Bush K, Freeman BA: Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparan complexes. Arch Biochem Biophys 1997, 339(2):125–135.

18. Sasaki S, Iwata M: Ultrastructural study of synapses in the anterior horn neurons of patients with amyotrophic lateral sclerosis. Neurol Sci 1996, 17(1):5–11.

19. Wang JC, Hao JK, Feng SL: Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis. J Neurosci Res 1996, 45:276–281.
35. Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM: Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999, 46:787–790.

36. Jaiswal MK: Calcium, mitochondria and the pathogenesis of ALS: the good, the Bad and the ugly. Front Cell Neurosci 2013, 7:199.

37. Carrido SG, Senn SL, Yin HZ, Weiss JH: AMPA induces excitotoxic mitochondrial Ca2+ overload and ROS generation in spinal motor neurons in vitro. J Neurol 2000, 20:240–250.

38. Beal MF: Oxidatively modified proteins in aging and disease. Free Radic Biol Med 2002, 32:797–803.

39. Menzies FM, Cookson MR, Taylor RW, Turnbull DM, Chrzanowska-Lightowlers ZM, Dong L, Figuelewicz DA, Shaw PJ: Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 2002, 125:1522–1533.

40. Beers DR, Ho BK, Sikors L, Alexianu ME, Mosier DR, Habib Mohamed A, Otsuka Y, Kazovka ME, Smith RE, McAlhany RG, Appel SH: Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis. J Neurochem 2001, 79:499–509.

41. Heath PR, Shaw PJ: Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002, 26(4):438–458.

42. Rao SD, Weiss JH: Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends Neurosci 2004, 27:17–21.

43. Maragkis NJ, Rothstein JD: Glutamate transporters in neurologic disease. Arch Neurol 2001, 58(3):365–370.

44. Trotti D, Roffa A, Danko CT, Brown RH, Hediger MA: SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurol 1999, 2:247–243.

45. Tatemoto K, Sadakata H, Tanaka M, Itagawa S, Shin RM, Miura M, Masuda M, Aota K, Ushikita M, Misawa H, Takahashi R: Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum Mol Genet 2004, 13:2183–2196.

46. Rao SD, Yin HZ, Weiss JH: Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. J Neurosci 2003, 23:2627–2633.

47. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K, Tateno M, Sadakata H, Tanaka M, Itohara S, Shin RM, Miura M, Masuda M, Aota K, Ushikita M, Misawa H, Takahashi R: Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum Mol Genet 2004, 13:2183–2196.

48. Proctor MA, Heath PR, Shaw PJ: Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002, 26(4):438–458.

49. Deardorff M, Rohleder J, Brown RH, Hediger MA: SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurol 1999, 2:247–243.

50. Tatemoto K, Sadakata H, Tanaka M, Itagawa S, Shin RM, Miura M, Masuda M, Aota K, Ushikita M, Misawa H, Takahashi R: Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum Mol Genet 2004, 13:2183–2196.

51. Germano K, Trout B, Keller BJ: Differential calcium buffering in motoneuron and their nonneuronal neighbors. J Neurosci 2005, 25(21):4916–4929.

52. Lipton SA, Kelly KM, Wertz S, Sanberg PR: Mitochondrial dysfunction and sporadic ALS. Trends Neurosci 2002, 25(2):65–70.

53. Jaiswal MK: The basic aspects of therapeutics in amyotrophic lateral sclerosis. J Neurol 2003, 250:–.

54. Pettegrew JW, Przedborski S: Mitochondrial dysfunction and sporadic ALS. Trends Neurosci 2002, 25(2):65–70.

55. Jaiswal MK: Amyotrophic lateral sclerosis: proposed mechanisms and pathways to treatment. Trends Neurosci 2003, 26(1):4–11.

56. Sherratt DJ, Nathans J: Calcium signaling in axonal transport and morphology are common pathological denominators in motor neuron disease and sporadic ALS. J Neurosci 2007, 27(3):987–993.

57. Jaiswal MK: Amyotrophic lateral sclerosis. Curr Opin Rheumatol 2007, 19(3):191–197.

58. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

59. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

60. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

61. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

62. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

63. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

64. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

65. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

66. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

67. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

68. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

69. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

70. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

71. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.

72. Lu YM, Yin HZ, Weiss JH: CA2+-permeable AMPA/kainate channels permit rapid injurious CA2+ entry. J Neurophysiol 1995, 73(6):1897–1904.
SOD1 and TDP43 ALS mouse models. *Hum Mol Genet* 2013. Nov. 25 [Epub ahead of print].

82. Maguire J, Sahavneh MA, Przedborski S, Estévez AG, Manfredi G. Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. *J Neurosci* 2012; 32(23):242–247.

83. Cozzolino M, Ferri A, Valle C, Carrì MT. Mitochondrial and ALS: Implications from novel genes and pathways. *Mol Cell Neurosci* 2013; 53:54–60.

84. Cozzolino M, Carrì MT. Mitochondrial dysfunction in ALS. *Prog Neurobiol* 2012; 97(2):54–66.

85. Vijayvergara C, Beal MF, Buck J, Manfredi G. Mutant superoxide dismutase I forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. *J Neurosci* 2005; 25(10):2483–2470.

86. Vande Velde C, Miller TM, Cashman NR, Cleveland DW. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. *Proc Natl Acad Sci U S A* 2008; 105(10):4022–4027.

87. Vande Velde C, McDonald KL, Bukhedemi Y, McAlonie-Downes M, Lobisger CS, Bel Hadj S, Zandona A, Julien JP, Shah SB, Cleveland DW. Misfolded SOD1 associated with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical onset. *Proc Natl Acad Sci* 2011; 108(3):e22031.

88. Bowling AC, Schulz JB, Brown RH Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. *J Neurochem* 1993; 61(6):2322–2325.

89. Browne SE, Bowling AC, Bal M, Gurney M, Brown RH, Beal MF. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. *J Neurochem* 1998; 71:281–287.

90. Jaarsma D, Roggnon F, Duijn WW, Verspaget HW, Haasdijk ED, Holstege JC. Cu-Zn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. *Acta Neuropathol* 2001; 102:293–305.

91. Hirano A, Nakano I, Kurland LT, Mulder DW, Holley PW, Saccomanno G. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. *J Neuropathol Exp Neurol* 1984; 43:471–480.

92. Hirano A. Cytopathology of amyotrophic lateral sclerosis. *Adv Neurol* 1991; 56:91–101.

93. Siklos L, Engelsdor J, Harati Y, Smith RG, Joo F, Appel SH. Jaiswal MK, Zech W, Goos M, Leutbecher C, Ferri A, Zippelius A, Carrì MT, Nau Jaiswal. Mitochondrial dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis mice. *J Neurochem* 2001; 77(5):164–172.

94. Vanselow BK, Keller BU. Chronic mitochondrial inhibition induces selective motoneuron death in vitro: a new model for amyotrophic lateral sclerosis. *J Neurochem* 2000; 74:1158–1165.

95. Bogaert E, Van Damme P, Robberecht W, Van Den Bosch L. VEGF protects motor neurons against excitotoxicity by upregulation of Glur2. *Neurobiol Aging* 2010; 31:2185–2191.

96. Oosthuyse B, Moons L, Storkebaum E, Shaw C, Ludolph AC, Leigh NP, Comi GP, Gasser T, Shaw PJ, Morrison KE, Vught PW, Khan S, Marklund SL, Brockington A, van Marion I, Anneser J, Fine GN, Hansen V, Beckman L, Adolfsson R, Fall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Derwichen M, Shaw C, Moons L, Vlitenck L, Morrison KE, Robberecht W, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. *Nat Genet* 2007; 39(3):383–394.

97. Cheng Z, Mennesmo I, Fadler B, Hinter J. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. *Ann Neurol* 2004; 56:564–567.

98. Azzouz M, Walsh GS, Storkebaum E, Walsmley LE, Mitrophanous KA, Kingsman SM, Carmeliet P, Mazarakis ND. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. *Nature* 2004; 429:413–417.

99. Wang Y, Ou Mao X, Xie L, Banwait S, Marti HH, Greenberg DA, Jin K. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. *J Neurosci* 2013; 33:4657–4671.

100. Kaal EC, Vlug AS, Verheijen MW, Kullman M, Joosten EA, Bar PR. Chronic mitochondrial inhibition induces selective motoneuron death in vitro: a new model for amyotrophic lateral sclerosis. *J Neurochem* 2000; 74:1158–1165.

101. Tovar-y-Romo LB, Tapia, R. Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo. *ASN Neuro* 2012; 4:e00081.

102. Lunn JS, Sakowski SA, Kim B, Rosenberg AA, Feldman EL. Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration. *Dev Neurobiol* 2009; 69:871–884.

103. Bergmann F, Keller BU. Chronic mitochondrial inhibition induces selective motoneuron death in vitro: a new model for amyotrophic lateral sclerosis. *J Neurochem* 2000; 74:1158–1165.

104. Sheehan JP, Maguire RS, Pattee G, Juel VC. Endoplasmic reticulum calcium uptake in mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. *J Neurochem* 2003; 84:164–170.

105. Higgins CMJ, Jung C, Xu Z. Survival improvement in G93A-SOD1 mouse model of familial amyotrophic lateral sclerosis mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD1: a model of familial amyotrophic lateral sclerosis (FALS). *Brain Res* 1995; 676:25–40.

106. Bendotti C, Calvanesi N, Chiveri L, Prelli A, Moggio M, Braga M, Silani V, De Biasi S. Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. *J Neurosci* 2001; 21:935–943.
119. Elliott JL, Snider WD: Parvalbumin is a marker of ALS-resistant motor neurons. *Neuroreport* 1995, 6(3):449–452.
120. Zhou Z, Neher E: Mobile and immobile calcium buffers in bovine adrenal chromaffin cells. *J Physiol* 1993, 469:245–273.
121. Klingauf J, Neher E: Modeling buffered Ca2+ diffusion near the membrane: implications for secretion in neuroendocrine cells. *Biophys J* 1997, 72:674–698.
122. Lips MB, Keller BJ: Activity-related calcium dynamics in motoneurons of the nucleus hypoglossus from mouse. *J Neurophysiol* 1999, 82:2936–2946.
123. Dekkers J, Bayley P, Dick JR, Schwaller MW, Greensmith L: Over-expression of parvalbumin in transgenic mice rescues motoneurons from injury-induced cell death. *Neuroscience* 2004, 123(2):459–466.
124. Rizzuto R, Brini M, Pozzan T: Intracellular targeting of the photoprotein aequorin: a new approach for measuring, in living cells, Ca2+ concentrations in defined cellular compartments. *Cytotechnology* 1993, 11:44–46.
125. Roy J, Minotti S, Dong L, Figlewicz DA, Durham HD: Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. *J Neurosci* 1998, 18:9673–9684.
126. Maragakis NJ, Rothstein JD: Glutamate transporters: animal models to neurologic disease. *Neurobiol Dis* 2004, 15(3):461–473.
127. Morotz GM, De Vos KJ, Vagnoni A, Ackerley S, Shaw CE, Miller CC: Amyotrophic lateral sclerosis-associated mutant VAPB/56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria. *Hum Mol Genet* 2012, 21:1979–1988.
128. De Vos KJ, Morotz GM, Stoica R, Tudor EL, Lau KF, Ackerley S, Warley A, Shaw CE, Miller CC: VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis. *Hum Mol Genet* 2012, 21:1299–1311.
129. Appel SH, Smith RG, Alexianu M, Siklos L, Engelhardt J, Colom LV, Stefani E: Maragakis NJ, Rothstein JD: Decreased glutamate transport by the brain and spinal cord in amyotropic lateral sclerosis. *N Engl J Med* 1992, 326(22):1464–1468.
130. Baron KT, Wang GJ, Elsaye RA, Saltor JD: Calcium and mitochondria. *FEBS Lett* 2004, 567:6–102.
131. Choi D, Koh J, Peters S: Motor neurons are selectively vulnerable to amyotrophic lateral sclerosis-associated mutant VAPBP56S. *Hum Mol Genet* 2005, 14(17):2013–2021.
132. Velumian A, MacDonald J, Carlen P, Abramow-Newerly W, Roder J: Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity pathophysiology. *Neuron* 1997, 19(4):373–386.
133. Carriedo SG, Yin HZ, Weiss JH: Intracellular targeting of the photoprotein aequorin to regulate calcium homeostasis. *Neuron* 1997, 19(4):373–386.
134. Carriedo SG, Yin HZ, Weiss JH: Intracellular targeting of the photoprotein aequorin to regulate calcium homeostasis. *Neuron* 1997, 19(4):373–386.
135. Rothstein JD, Martin LJ, Kuncl RW: Decreased glutamate uptake by a subset of mitochondria in hippocampal neurons. *Brain Res* 2003, 993:124–132.
136. Jia Z, Agopyan N, Miu P, Xiong Z, Henderson J, Gerlai R, Taverna FA, Denton RM: Subcellular imaging of intramitochondrial Ca2+ with recombinant targeted aequorin: Significance for the regulation of pyruvate dehydrogenase activity. *Proc Natl Acad Sci U S A* 1996, 93:5468–5494.
137. Jaiswal MK, Balakrishnan S, Ebert S, Mitchell T, Carrì A: Spatial profiles of store-dependent calcium release in motoneurons of the nucleus hypoglossus from newborn mouse. *J Physiol* 2003, 547(775–787.
138. Duchen MR: Mitochondria and Ca2+ in cell physiology and pathophysiology. *Cell Calcium* 2000, 28:339–348.
139. Rizzuto R, Duchen MR, Pozzan T: Flirting in little space: the ER/mitochondria Ca2+ liaison. *Sci STKE* 2004, 1(215).r1.
140. Goos M, Zech WD, Jaiswal MK, Balakrishnan S, Ebert S, Mitchell T, Carri A, Keller BJ: Additive neuroprotective effects of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. *Biomed Pharmacother* 2003, 57:1056–1061.
141. Tognoni G, Tuchschmid MH, Marchioli R, Montiero A, Natale G, Gobbo T, Turrioni E, Angelini C, D’Avola D, Tavazzi L, Tognoni G, Tognoni G: Excitocitic calcium overload in a subpopulation of mitochondria triggers delayed death in hippocampal neurons. *J Neurosci* 2004, 24:5611–5622.
142. Shaw PJ: Molecular and cellular pathways of neurodegeneration in motor neuron disease. *J Neurol Neurosurg Psychiatry* 2005, 76:1046–1057.
143. Geng B, Drzalinek PH: Moving forward in clinical trials for ALS: motor neuron diseases lead the way please. *Drug Discov Today* 2013, doi:10.1016/j.drudis.2013.10.014. [Epub ahead of print].
144. Carri MT, Grignaschi G, Bendotti C: Targets in ALS: designing multidrug therapies. *Trends Pharmacol Sci* 2006, 27(5):267–273.
145. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH: Retrograde viral delivery of bFGF1 prolongs survival in a mouse ALS model. *Science* 2003, 301:839–842.
146. Tolosa L, Mir M, Asensio VJ, Olmos G, Llado J: Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. *J Neurochem* 2008, 105:1080–1090.
147. Tovar-Romo LB, Tapia R: VEGF protects spinal motor neurons against chronic excitotoxic degeneration in vivo by activation of PI3K-pathway and inhibition of p38MAPK. *J Neurochem* 2010, 115:1090–1101.
148. Zhang W, Narayanan M, Friedlander RM: Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. *Ann Neurol* 2003, 53:267–270.
149. Gabaouza-Davis S, Willing AE, Zgoba T, Saporta S, Justen EB, Lane JC, Hudson JE, Chen N, Davis CD, Sanberg PR: Intravenous administration of neighboring endoplasmic reticulum regions. *J Biol Chem* 2001, 276:29430–29439.
150. Szabadkai G, Simoni AM, Rizzuto R: Mitochondrial Ca2+ uptake requires sustained Ca2+ release from the endoplasmic reticulum. *J Biol Chem* 2003, 278:15153–15161.
151. Rothstein JD, Martin LJ, Kuncl RW: Decreased glutamate transport by the brain and spinal cord in amyotropic lateral sclerosis. *N Engl J Med* 1992, 326(22):1464–1468.
152. Baron KT, Wang GJ, Elsaye RA, Saltor JD: Calcium and mitochondria. *Brain Res* 2003, 993:124–132.
153. Malli R, Frieden M, Osibow K, Zoratti C, Mayer M, Demaurex N, Graier WF: Sustained Ca2+ transfer across mitochondria is essential for mitochondrial Ca2+-buffering, store-operated Ca2+ entry, and Ca2+ store refilling. *J Biol Chem* 2004, 285:44769–44779.
154. Rizzuto R, Bernardi P, Pozzan T: Mitochondria as all-round players of the calcium game. *J Physiol* 2000, 529:37–47.
155. Coronado JC, Tapia R: Ca2+-permeable AMPA receptors and intracellular Ca2+ determine motoneuron vulnerability in rat spinal cord in vivo. *Neuropharmacology* 2007, 52:1219–1228.
156. Gabbay SRC, Yeh DI, Gunter KK, Eliseev RA, Saltor JD: Calcium and mitochondria. *FEBS Lett* 2004, 567:6–102.
157. Rizzuto R, Bastianutto C, Brini M, Muriga M, Pozzan T: Mitochondrial Ca2+ homeostasis in intact cells. *J Cell Biol* 1996, 132:1183–1194.
158. Rizzuto R: Calcium mobilization from mitochondria in synaptic transmitter release. *J Cell Biol* 2003, 160:441–443.
159. Rutter GA, Burnett P, Rizzuto R, Brini M, Muriga M, Pozzan T, Tavare JM, Denton RM: Subcellular imaging of intramitochondrial Ca2+ with recombinant targeted aequorin: Significance for the regulation of pyruvate dehydrogenase activity. *Proc Natl Acad Sci U S A* 1996, 93:5495–5499.
160. Jaiswal MK, Balakrishnan S, Ebert S, Mitchell T, Carrì A, Keller BJ: Spatial profiles of store-dependent calcium release in motoneurons of the nucleus hypoglossus from newborn mouse. *J Physiol* 2003, 547:775–787.
human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation.

*J Hematotherapy Stem Cell Res* 2003, 12:255–270.

164. Lepore AC, Maragakis NJ: Targeted stem cell transplantation strategies in 
ALS. *Neurochem Internat* 2007, 50:966–975.

165. Bova MP, Kinney GG: Emerging drug targets in amyotrophic lateral 
sclerosis. *Expert Opin Orphan Drugs* 2013, 1(1):5–20.

doi:10.1186/2052-8426-2-26

Cite this article as: Jaiswal: Selective vulnerability of motoneuron and perturbed mitochondrial calcium homeostasis in amyotrophic lateral sclerosis: implications for motoneurons specific calcium dysregulation. *Molecular and Cellular Therapies* 2014 2:26.